Data from: Association of CD14 with incident dementia and markers of brain aging and injury

Objective To test the hypothesis that the inflammatory marker plasma
soluble CD14 (sCD14), associates with incident dementia and related
endophenotypes in two community-based cohorts. Methods. Our samples
included the prospective community-based Framingham Heart Study (FHS) and
Cardiovascular Health Study (CHS) cohorts. Plasma sCD14 was measured at
baseline and related to the incidence of dementia, domains of cognitive
function, and MRI defined brain volumes. Follow-up for dementia occurred
over a mean of 10 years (SD, 4) in the FHS and a mean of 6 years (SD, 3)
in the CHS. Results We studied 1588 participants from the FHS (mean age
69±6 years, 47% male,131 incident events) and 3129 participants from the
CHS (mean age 72±5 years, 41% male, 724 incident events) for the risk of
incident dementia. Meta-analysis across the two cohorts showed that each
standard deviation unit increase in sCD14 was associated with a 12%
increase in the risk of incident dementia (95% confidence interval [CI],
1.03 to 1.23; P=0.01) following adjustments for age, sex, APOE ε4 status,
and vascular risk factors. Higher levels of sCD14 were associated with
various cognitive and MRI markers of accelerated brain aging in both
cohorts and with a greater progression of brain atrophy and a decline in
executive function in the FHS. Conclusion. sCD14 is an inflammatory marker
related to brain atrophy, cognitive decline, and incident dementia.